Real-time Estimate
Cboe BZX
02:54:36 2024-04-30 pm EDT
|
5-day change
|
1st Jan Change
|
0.805
USD
|
+13.03%
|
|
+50.76%
|
-60.67%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
76.61
|
150.8
|
113.6
|
58.88
|
91.77
|
36.29
|
-
|
-
|
Enterprise Value (EV)
1 |
76.61
|
150.8
|
113.6
|
58.88
|
91.77
|
36.29
|
36.29
|
36.29
|
P/E ratio
|
-3.05
x
|
-6.45
x
|
-8.16
x
|
-1.96
x
|
-3.15
x
|
-1.03
x
|
-0.79
x
|
-1.4
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
75.4
x
|
8.12
x
|
-
|
24,215
x
|
6.93
x
|
3.04
x
|
1.03
x
|
EV / Revenue
|
-
|
75.4
x
|
8.12
x
|
-
|
24,215
x
|
6.93
x
|
3.04
x
|
1.03
x
|
EV / EBITDA
|
-3.6
x
|
-
|
-8.96
x
|
-
|
-
|
-0.56
x
|
-0.53
x
|
-
|
EV / FCF
|
-
|
-22.7
x
|
-
|
-2.27
x
|
-
|
-0.94
x
|
-1
x
|
-1.78
x
|
FCF Yield
|
-
|
-4.41%
|
-
|
-44.1%
|
-
|
-106%
|
-99.8%
|
-56.1%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
17,101
|
24,884
|
28,407
|
36,121
|
44,122
|
50,958
|
-
|
-
|
Reference price
2 |
4.480
|
6.060
|
4.000
|
1.630
|
2.080
|
0.7122
|
0.7122
|
0.7122
|
Announcement Date
|
3/25/20
|
3/25/21
|
3/28/22
|
3/30/23
|
3/18/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
2
|
14
|
-
|
0.00379
|
5.235
|
11.93
|
35.08
|
EBITDA
1 |
-21.29
|
-
|
-12.68
|
-
|
-
|
-64.58
|
-68.67
|
-
|
EBIT
1 |
-21.31
|
-19.79
|
-12.9
|
-26.91
|
-25.41
|
-31.26
|
-41.66
|
-23.91
|
Operating Margin
|
-
|
-989.46%
|
-92.17%
|
-
|
-670,354.88%
|
-597.25%
|
-349.14%
|
-68.16%
|
Earnings before Tax (EBT)
1 |
-21.16
|
-19.77
|
-12.78
|
-28.01
|
-27.26
|
-32.12
|
-42.73
|
-24.79
|
Net income
1 |
-21.16
|
-19.77
|
-12.78
|
-28.01
|
-27.26
|
-32.12
|
-42.43
|
-24.79
|
Net margin
|
-
|
-988.49%
|
-91.27%
|
-
|
-719,290.24%
|
-613.65%
|
-355.58%
|
-70.67%
|
EPS
2 |
-1.470
|
-0.9400
|
-0.4900
|
-0.8300
|
-0.6600
|
-0.6933
|
-0.8975
|
-0.5100
|
Free Cash Flow
1 |
-
|
-6.646
|
-
|
-25.98
|
-
|
-38.53
|
-36.23
|
-20.36
|
FCF margin
|
-
|
-332.28%
|
-
|
-
|
-
|
-735.97%
|
-303.64%
|
-58.05%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/25/20
|
3/25/21
|
3/28/22
|
3/30/23
|
3/18/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
-
|
10
|
-
|
-
|
-
|
-
|
-
|
-
|
0.0012
|
0.00259
|
0.6375
|
0.79
|
1.124
|
1.584
|
EBITDA
|
-5.832
|
3.187
|
-6.203
|
-6.014
|
-6.218
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-5.905
|
3.113
|
-7.188
|
-7.121
|
-7.23
|
-5.372
|
-5.459
|
-5.961
|
-6.52
|
-7.467
|
-7.749
|
-7.986
|
-8.043
|
-8.108
|
Operating Margin
|
-
|
31.13%
|
-
|
-
|
-
|
-
|
-
|
-
|
-543,349.17%
|
-288,283.78%
|
-1,215.53%
|
-1,010.93%
|
-715.57%
|
-512.01%
|
Earnings before Tax (EBT)
1 |
-5.569
|
2.983
|
-7.34
|
-7.239
|
-7.309
|
-6.123
|
-5.739
|
-6.216
|
-7.339
|
-7.967
|
-7.969
|
-8.202
|
-8.256
|
-8.317
|
Net income
1 |
-5.569
|
2.983
|
-7.34
|
-7.239
|
-7.309
|
-6.123
|
-5.739
|
-6.216
|
-7.339
|
-7.967
|
-7.969
|
-8.202
|
-8.256
|
-8.317
|
Net margin
|
-
|
29.83%
|
-
|
-
|
-
|
-
|
-
|
-
|
-611,560.83%
|
-307,611.58%
|
-1,249.99%
|
-1,038.23%
|
-734.52%
|
-525.25%
|
EPS
2 |
-0.2100
|
0.1000
|
-0.2400
|
-0.2200
|
-0.2100
|
-0.1700
|
-0.1500
|
-0.1600
|
-0.1800
|
-0.1600
|
-0.1733
|
-0.1767
|
-0.1800
|
-0.1767
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/10/21
|
3/28/22
|
5/12/22
|
8/10/22
|
11/10/22
|
3/30/23
|
5/12/23
|
8/10/23
|
11/13/23
|
3/18/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-6.65
|
-
|
-26
|
-
|
-38.5
|
-36.2
|
-20.4
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
0.26
|
-
|
0.87
|
-
|
4
|
4
|
4
|
Capex / Sales
|
-
|
13.06%
|
-
|
-
|
-
|
76.41%
|
33.52%
|
11.4%
|
Announcement Date
|
3/25/20
|
3/25/21
|
3/28/22
|
3/30/23
|
3/18/24
|
-
|
-
|
-
|
Last Close Price
0.7122
USD Average target price
9.333
USD Spread / Average Target +1,210.49% Consensus |
1st Jan change
|
Capi.
|
---|
| -65.76% | 36.29M | | +26.47% | 664B | | +30.33% | 567B | | -6.33% | 354B | | +19.35% | 330B | | +4.23% | 286B | | +14.25% | 234B | | +4.91% | 199B | | -10.10% | 196B | | -4.04% | 148B |
Other Pharmaceuticals
|